PubMed=8423216; DOI=10.1172/JCI116168
Fagin J.A., Matsuo K., Karmakar A., Chen D.L., Tang S.H., Koeffler H.P.
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
J. Clin. Invest. 91:179-184(1993)
PubMed=11439348; DOI=10.1038/sj.onc.1204531
Frasca F., Vigneri P., Vella V., Vigneri R., Wang J.Y.J.
Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to hepatocyte growth factor.
Oncogene 20:3845-3856(2001)
PubMed=14522906
Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R., Vigneri P.
p73 tumor-suppressor activity is impaired in human thyroid cancer.
Cancer Res. 63:5829-5837(2003)
PubMed=16924234; DOI=10.1038/sj.onc.1209899
Yu W., Imoto I., Inoue J., Onda M., Emi M., Inazawa J.
A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity.
Oncogene 26:1178-1187(2007)
PubMed=18713817; DOI=10.1210/jc.2008-1102
Schweppe R.E., Klopper J.P., Korch C., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A., Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)
PubMed=20143388; DOI=10.1002/ijc.25242
Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A., MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R., Freshney R.I.
Check your cultures! A list of cross-contaminated or misidentified cell lines.
Int. J. Cancer 127:1-8(2010)
PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690
Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.
Clin. Cancer Res. 17:7248-7264(2011)
400 179 0116
